BlogFrom Deviation to CAPA: How AI Helps Teams Find and Fix Root Causes

Three deviations on the same packaging line in one year. Each was investigated. Each was closed as operator error. Each operator was retrained. And then it happened a fourth time.

Stories like this play out at GMP sites everywhere, and regulators know it. For years, failure to thoroughly investigate discrepancies under 21 CFR 211.192 has ranked among the most cited problems in FDA drug inspections. In fiscal year 2025 it was the second most cited section of the drug GMP rules, with 164 observations. The issue is rarely that deviations go unrecorded. It is that investigations are rushed, connections are missed and fixes do not last. This is exactly where AI can help.

What GMP expects from investigations and CAPA

Under 21 CFR 211.100, any deviation from written procedures must be recorded and justified. Under 21 CFR 211.192, any unexplained discrepancy must be thoroughly investigated, and the investigation must extend to other batches that may have been affected.

ICH Q10, the international model for pharmaceutical quality systems, places corrective and preventive action, or CAPA, at the centre of the quality system. Actions should flow from investigations, and their effectiveness should be verified. ICH Q9(R1) adds that the depth of each investigation should match the level of risk involved.

In short, regulators expect three things: find the real cause, fix it properly and prove the fix worked.

Where deviation management breaks down

The first problem is volume. Investigations pile up faster than teams can close them, and due dates slip. The second is fragmentation. The information needed to investigate well is spread across QMS records, spreadsheets, emails and paper files, often across several sites and legacy systems that are hard to search.

This makes connections hard to see. A deviation that looks new may be the fourth occurrence of the same underlying problem, but no one links it to the earlier cases. Under time pressure, root causes are often closed as human error, and retraining becomes the default fix. Once the CAPA is closed, there is frequently no follow up to confirm it actually stopped the problem from returning.

How AI supports better investigations

AI adds value at every stage of the deviation lifecycle. When a new report arrives, AI can read it, suggest a category and risk level, and route it to the right owner, so serious events get attention quickly.

Its most powerful role comes during the investigation itself. AI can search the full history of deviations across products, lines and sites, including records held in older systems, and surface similar past events in minutes. It can then highlight links that people may miss: the same piece of equipment, the same shift, the same supplier lot or the same step in a procedure.

Once actions are agreed, AI can track each CAPA to closure, send reminders as deadlines approach and prompt effectiveness checks at the right time. Over months, it can summarise deviation trends for management review and annual product quality reviews, showing where problems cluster and whether they are improving.

Moving past human error

Return to the packaging line. Seen one at a time, each deviation looked like an individual mistake. When AI shows that all four occurred at the same step, using the same work instruction, the question changes. It is no longer "who made the mistake" but "what in our process makes this mistake easy to make".

That shift leads to better fixes: a clearer instruction, a redesigned line clearance step, an equipment change or targeted training at the point of risk. These are the kinds of root causes that actually stop problems from coming back, and the kinds of investigations inspectors want to see.

Labeling deviations are a good example. A wrong label version on the line, a misprinted batch code or a carton with an outdated warning is often closed as a one off mistake on the packaging floor. Yet the real cause usually sits further upstream, in how artwork was approved or how printed labels were checked on receipt. Checking every artwork file against the approved copy and regulatory rules before print, and again when labels arrive from the printer, removes a whole category of deviations at the source instead of investigating them one at a time.

Keeping AI in the right role

In deviation management, AI is a research assistant, not a decision maker. It finds, sorts and connects information. The investigator reviews the evidence, determines the root cause and approves the conclusion. Every pattern AI suggests should link back to the original records, so investigators can verify the evidence for themselves.

This matters more than ever. In April 2026, the FDA issued its first warning letter citing the inappropriate use of AI in drug manufacturing, after a firm put AI generated documents into use without proper review by its quality unit. The lesson is clear: AI output that supports GMP decisions must be reviewed and approved by qualified people.

If AI feeds into GMP decisions or records, the tool should also be validated for that intended use, with the level of validation matched to the risk, as GAMP 5 Second Edition recommends. Access to deviation data should follow the same controls as the QMS itself.

Measuring the difference

The impact shows up in a handful of measures: the share of investigations closed on time, the rate of repeat deviations, the share of CAPAs verified as effective, and the average time from deviation to confirmed root cause. Of these, a falling repeat rate is the clearest sign that root causes are being found and fixed rather than simply recorded.

Deviations will always happen. With AI connecting the dots, each one becomes an opportunity to make the process stronger, rather than another entry in the backlog.

Benchmark IT Solutions builds AI solutions that read deviation reports, investigation records and CAPA data across systems. Talk to us about finding the patterns in your quality data.